Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
James Blackstone, Thomas Williams, Jennifer M Nicholas, Ekaterina Bordea, Floriana De Angelis, Alessia Bianchi, Alberto Calvi, Anisha Doshi, Nevin John, Sean Apap Mangion, Charles Wade, Rachel Merry, Gil Barton, Dawn Lyle, Elisabeth Jarman, Don Mahad, Abdullah Shehu, Tarunya Arun, Gavin McDonnell, Ruth Geraldes, Matthew Craner, Charles Hillier, Jeban Ganesalingam, Leonora Fisniku, Jeremy Hobart, Cord Spilker, Neil Robertson, Seema Kalra, Stefano Pluchino, Sreedharan Harikrishnan, Miriam Mattoscio, Timothy Harrower, Carolyn Young, Martin Lee, Suresh Chhetri, Fayyaz Ahmed, David Rog, Eli Silber, Paul Gallagher, Martin Duddy, Agne Straukiene, Richard Nicholas, Claire Rice, Stuart J Nixon, Judy Beveridge, Annie Hawton, Susan Tebbs, Marie Braisher, Gavin Giovannoni, Olga Ciccarelli, John Greenwood, Alan J Thompson, Rachael Hunter, Sue Pavitt, Owen Pearson, Nikos Evangelou, Basil Sharrack, Ian Galea, Siddharthan Chandran, Helen L Ford, Chris Frost, Jeremy Chataway
BMJ Open Sep 2024, 14 (9) e086414; DOI: 10.1136/bmjopen-2024-086414
